CVS Health Offers Genomic Testing for More Precise Care

Targeted therapies have made tremendous progress in oncology, with some products essentially rendering certain cancers chronic conditions. According to the National Cancer Institute, the FDA has approved hundreds of targeted therapies across 30 types of cancers. Genomic testing can help determine whether a patient is a candidate for a particular therapy, and CVS Health has launched a program focused on boosting patient access to this.

The PBM is offering its Transform Oncology Care program via a collaborative with precision medicine-focused technology company Tempus. The program uses the testing results at the point of prescribing so patients are started on the treatment appropriate for them in a timely fashion. It also matches patients to clinical trials for which they are eligible. AIS Health recently spoke with Prem Shah, Pharm.D., executive vice president of specialty and product innovation for CVS Health, to learn more about the program.

© 2022 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

workers-prepping-infusion-drug
May 12

Major PBMs Look Ahead to 2023 for Biosimilars Boom

READ MORE
wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
pills-and-dollars
May 12

Study: With High Prices, Rebate Revenue Is Growing for PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today